RIGEL PHARMACEUTICALS INC
For the period ended Dec 31, 2025. Filed Mar 3, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 3, 2026
RIGL$43.91+4.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Cash Flows
(In thousands)
| Year Ended December 31, | |||
|---|---|---|---|
| 2025 | 2024 | 2023 | |
| Operating activities | |||
| Net income (loss) | $367,024 | $17,485 | $(25,091) |
| Adjustments to reconcile net income (loss) to net cash provided by operating activities: | |||
| Stock-based compensation expense | 12,711 | 12,393 | 8,806 |
| (Gain) loss on sale and disposal of fixed assets | — | (79) | 266 |
| Depreciation and amortization | 2,415 | 2,228 | 1,238 |
| Deferred income tax benefit | (245,852) | — | — |
| Release of cost share liability | (39,981) | — | — |
| Net amortization of discount on short-term investments and term loans | (1,150) | (709) | (479) |
| Changes in assets and liabilities: | |||
| Accounts receivable, net | (10,148) | (11,065) | 9,770 |
| Inventories | (5,635) | 764 | 1,172 |
| Prepaid and other current and non-current assets | (11,848) | (3,440) | 2,054 |
| Right-of-use assets | (674) | 615 | 1,069 |
| Accounts payable | 3,852 | (3,803) | (366) |
| Accrued compensation | 1,775 | 1,463 | (190) |
| Accrued research and development | 1,451 | 560 | (4,195) |
| Revenue reserves and refund liability | 1,276 | 10,756 | 3,539 |
| Other current and long-term liabilities | (285) | 4,995 | (2,208) |
| Lease liability | 724 | (692) | (1,128) |
| Net cash provided by (used in) operating activities | 75,655 | 31,471 | (5,743) |
| Investing activities | |||
| Maturities of short-term investments | 61,129 | 39,700 | 41,650 |
| Purchases of short-term investments | (153,494) | (35,272) | (31,206) |
| Capital expenditures | — | (36) | — |
| Payments for acquisition of intangible assets | — | (360) | (15,000) |
| Proceeds from sale of property and equipment | — | 98 | 259 |
| Net cash (used in) provided by investing activities | (92,365) | 4,130 | (4,297) |
| Financing activities | |||
| Net proceeds from term loan financing | — | — | 19,950 |
| Principal payments of term loans | (7,500) | — | — |
| Net proceeds from issuance of common stock from equity plans | 8,101 | 1,964 | 1,049 |
| Closing purchase price payment related to asset acquisition | — | (10,000) | — |
| Cost share payments to a collaboration partner | — | (3,605) | (2,632) |
| Net cash provided by (used in) financing activities | 601 | (11,641) | 18,367 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | (16,109) | 23,960 | 8,327 |
| Cash and cash equivalents at beginning of period | 56,746 | 32,786 | 24,459 |
| Cash, cash equivalents, and restricted cash at end of period | $40,637 | $56,746 | $32,786 |
| Supplemental disclosure of cash flow information | |||
| Interest paid | $6,573 | $7,039 | $5,848 |
| Income taxes paid | 1,063 | 331 | 81 |
| Increase in right-of-use assets and lease liability | 1,220 | — | — |
| Acquisition-related liabilities | 5,000 | 5,000 | — |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.